The company is developing and making specialized medicines for treating multiple sclerosis, dermatological disorders, female health concerns, cancer and is creating new diagnostic imaging techniques. Berlex, Inc. is a pioneer in the imaging market. It has introduced a broad range of imaging agents. Its contribution began in 1988 with the introduction of the world's first magnetic resonance imaging agent, Magnevist® (gadopentetate dimeglumine) injection. Berlex is headquartered in New Jersey and the U.S. affiliate of Bayer Schering Pharma AG, Germany.